Catalyst Wire Dossier Catalyst Wire Dossier

Pimecrolimus 0.3% Ophthalmic Ointment

pimecrolimus · Famy Life Sciences (a Viatris Company)
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Pimecrolimus 0.3% Ophthalmic Ointment, covering 2026-01-07 to 2026-01-07. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment [Phase 3]

See pricing